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ABSTRACT
Objectives: Classical cytogenetic analysis remains a gold standard in invasive prenatal diagnosis. Recently, Microfluidics-
-FISH, a novel method based on FISH, has been introduced. This integral approach allows to obtain result for common 
aneuploidies within the same day from a much smaller sample of the amniotic fluid. In this study we compare effectiveness 
of Microfluidics-FISH to classical karyotype and Rapid FISH.
Material and methods: 52 samples of amniotic fluid were drawn from the pregnant women due to common indications. Cell 
cultures have been set up for classical cytogenetic analysis as well as amniotic cells have been loaded into the microchip of 
Microfluidics-FISH as well standard procedure of Rapid FISH was performed for evaluation of trisomy 21, 13, 18 chromosome 
and sex chromosomes numeric aberrations. 
Results: 9 samples out of 52 showed chromosomal aberrations in both FISH methods what was consistent with karyoty-
ping. One case of small supernumerary marker chromosome was detected only in the classical cytogenetic analysis. For 
the majority of cases turnaround time was shortest for Microfluidics-FISH and the average volume of sample was smallest. 
Microfluidics-FISH proved to be reliable and cost-effective rapid testing method of common aneuploidies. Recognizing, ho-
wever, limitations of methods based on FISH it cannot replace conventional karyotyping and be the sole method of diagnosis.
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INTRODUCTION
The aim of prenatal diagnosis is to detect congenital 
abnormalities of the fetus. Increasing number of defects 
can be treated in uterus or corrected after birth but a distinct 
amount of them is irreversible or even lethal. In those cases 
prenatal diagnosis allows parents to make an informed 
decision about course of the pregnancy as well health care 
professionals to optimize ante- and postnatal care. The most 
frequently identified chromosome abnormality in humans 
is aneuploidy (trisomy or monosomy), which occurs in at 
least 5% of all clinically recognized pregnancies [1]. Triso-
my for 13, 18 and 21 chromosome and X, Y chromosome 
aneuploidies are the most common prenatally diagnosed 
aberrations [2] and are responsible for more than 90% of 
live- born chromosomal abnormalities [3]. 
With application of modern molecular techniques such 
as: FISH, MLPA, QF-PCR, BoBs and aCGH allowing for much 
faster aneuploidy detection, new strategies have evolved. 
FISH, introduced to prenatal diagnosis in 1992 has proved to 
be effective and reliable method of detection on uncultured 
samples and considerably reduced reporting time [4–6]. 
Most centers applying this technique use commercially 
validated probe sets, which are expensive, and the protocols 
that are labor- intensive and time-consuming [7]. 
Microfluidics-FISH is a novel approach to prenatal dia-
gnosis in which a special device, MicroFIND®, is used. This 
IVD certified microchip allows to combine different steps of 
FISH into integral process, shortening the procedure so that 
results are available within 24 hours of amniocentesis. With 
reduced price of single test and shorter turnaround time 
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Microfluidics-FISH seems competitive to other available 
methods. 
OBJECTIVES
In this study we evaluate the use of Microfluidics-FISH 
in prenatal diagnosis comparing it to other methods com-
monly used in that field- classical karyotype and Rapid FISH.
MATERIAL AND METHODS
Samples of amniotic fluid were obtained from 52 pre-
gnant women between 15+1 and 28+5 weeks of pregnan-
cy basing on last menstrual period (LMP) or biparietal 
diameter (BPD) evaluated in ultrasound scan. The amnio-
centeses were performed in a consecutive series in one 
prenatal center due to standard indications: increased risk 
of common chromosomal aberrations in prenatal scre-
ening, advanced maternal age, abnormalities in ultrasound 
scan, suspicion of congenital defects or chromosomal 
aberration in preceding pregnancy, risk of monogenic 
disorder and extreme parental stress. Prior to that all wo-
men were counseled by medical geneticist, confirmed they 
understood disclosed information and gave their written 
informed consent. Each obtained sample of amniotic fluid 
(19–22 mL) was distributed for: karyotyping (10–14 mL), 
Rapid FISH (4–6 mL) and Microfluidics-FISH (1–4 mL), which 
were performed according to standard protocols adopted 
in our laboratory. 
In rare cases of Rapid FISH or Microfluidics-FISH failure 
the protocol was extended. Samples were reevaluated after 
repeating dehydration process and following steps with 
increased amount of probes and hybridization time.  
The comparison of results obtained with each applied 
technique was performed and statistical differences were 
measured with chi square test.
Sample collection for research was approved by Bio-
ethics Committee of Pomeranian Medical University in 
Szczecin, Poland. 
RESULTS
Of the 52 analyzed amniotic samples, chromosomal 
aberrations have been found in 10 of them, what comprises 
almost 20%. The most recurrent abnormality was trisomy 
for 21 chromosome, which occurred in 7 fetuses. All cases 
were classical trisomy and were also detected by both FISH 
methods. Other aberrations included single case of: mosaic 
trisomy for 18 chromosome (dominating trisomic cell line 
was identified in comparative percentage in all techniques), 
triploid (evident in all methods) and small supernumerary 
marker chromosome (sSMC) that was observed only in clas-
sical karyotyping but was not identified by Rapid FISH and 
Microfluidics-FISH. In the group in which abnormality was 
detected the accordance rate of both FISH techniques and 
classical cytogenetic analyses was 98% and the difference 
was not statistically significant.
 In remaining group of 42 cases, which consisted of 
24 female and 18 male fetuses no other aberration was 
found as their results were assessed as normal in all tech-
niques. An overview of anomalies found in the classical 
karyotype, juxtaposed to the results of both FISH methods, 
is shown in Table 1. 
Standard protocol allowed to obtain indicative results of 
classical karyotype in all patients. Regarding Rapid FISH and 
Table 1. The overview of anomalies detected by classical karyotype, compared to results of Rapid FISH and Microfluidics-FISH
Result Sex Classical karyotype Rapid FISH
Accordant  




Female 24 24 Yes 100% 24 Yes 100%
Male 18 18 Yes 100% 18 Yes 100%
Total 42 42 Yes 100% 42 Yes 100%
Abnormal
Trisomy 21
Female 4 4 Yes 100% 4 Yes 100%
Male 3 3 Yes 100% 3 Yes 100%
Triploidy Female 1 1 Yes 100% 1 Yes 100%
Mosaic trisomy 18 Female 1 1 Yes 100% 1 Yes 100%
SSMC Male 1 0 No 0% 0 No 0%
All abnormal
Female 6 6 Yes 100% 6 Yes 100%
Male 4 3 No 75% (3/4) 3 No 75%  (3/4)
Total 10 9 No 90% (9/10) 9 No 90% (9/10)
All All 52 52 No 98% (51/52) 52 No 98% (51/52)
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Microfluidics-FISH method it was 96% and 90% of samples, 
respectively. In order to achieve diagnostic result in 2 cases 
of Rapid FISH and 5 cases of Microfluidics-FISH extended 
protocol had to be applied. The need for reassessment was 
attributed to poor quality of samples related to their advan-
ced gestational age (20–29 weeks). No such problems were 
encountered in samples from 15–19 week of pregnancy.
The turnaround time was shortest for Microfluidics-FISH 
and ranged from 9 to 24 hours, depending on the quality of 
sample and other factors such as time of admission to the 
lab. The need to apply extended protocol doubled the time 
required to achieve diagnostic result for Microfluidics-FISH, 
as shown in Table 2.
 The determined cost was lowest for Microfluidics-FISH. 
It was nearly three and two times reduced comparing to 
classical karyotype and Rapid FISH, respectively. The need 
for extended protocol, which arose in almost 10% of cases 
in Microfluidics-FISH nearly, doubled the cost of a single 
assay. The cost analysis is also given in Table 2.
DISCUSSION
 In our study Microfluidics-FISH proved to be an accu-
rate and cost-effective rapid testing method of common 
aneuploidies, what is also consistent with results published 
by Yo et al. [8]. Chromosomal aberrations, existing in 20% 
of investigated samples, have been identified correctly by 
all methods in all but one case, in which fetus was diagno-
sed with sSMC. sSMC, which can only be seen in standard 
karyotyping, occurs at a rate of 0.65–1.5/1000 in prenatal 
diagnosis [9]. In our patient further molecular analysis re-
vealed it to be of 22 chromosome origin. As available kit of 
FISH probes is focused on 13, 18, 21, X and Y chromosome 
aneuploidies, this abnormality could not be detected and 
presents limitation of methods based on FISH. Almost 30% 
of chromosomal aberrations might not be detected by FISH 
based methods in prenatal diagnosis, concluded Evans et 
al. in their study which was an international, collaborative 
assessment of 146 000 prenatal cytogenetic results [10]. 
However, the question arises about their clinical relevance as 
balanced translocations were also counted. The prevalence 
of clinically significant aberrations that are not detected by 
rapid testing has been estimated at around 0.1% by Ogilvie 
et al. [7]. 
The most recurrent abnormality, trisomy for 21 chromo-
some was recognized appropriately in all samples and no 
false positive or negative results have been encountered in 
both FISH methods. Additionally, there was 100% accordance 
between FISH detected trisomy and ultrasound anomalies.
The most distinguishing feature of the group in which 
reevaluation with extended protocol was required, was 
their advanced gestational age (20–29 weeks) what relates 
to poor quality sample: reduced number of viable amniotic 
cells, excessive amount of cell debris and residual cytoplasm. 
The same problem was encountered in aforementioned 
study by Yo et al. [8]. In such cases, a higher concentration of 
pellet was needed and loading process had to be repeated. 
Altogether, it considerably increased cost and reporting time 
and linked with information about the need to reexamine 
deepened parental stress.
The volume of sample needed to perform test was smal-
lest for Microfluidics-FISH what was beneficial in cases of 
oligohydroamnios and when amniocentesis was technically 
difficult to perform. As only 1, 5 µl of pellet was required for 
a single analysis, in the event of its failure the remaining 
specimen could be tested. 
Comparing Microfluidics-FISH to the evaluated me-
thods, it was most affordable as its estimated cost comprised 
one third of the standard karyotype and half of the Rapid 
FISH. Taking into consideration other low-cost, molecular 
methods available on market, such as MLPA or QF-PCR the 
price of a single assay is still more competitive.
The turnaround time was also shortest for Microfluidics-
-FISH and ranged from 9 to 24 hours. Under favorable con-
ditions (sample admission in the morning, early pregnancy) 
the result was given within the same day of amniocentesis 
not compromising on its quality.
In light of these facts, the targeted group of Microflu-
idics-FISH test seems to be patients, in which amniocentesis 
was performed between 15–19 week of gestation due to 
very specific indications, increased risk of Down syndrome 
being the main one. As it is still leading reason of referral, 
that group is dominant in prenatal centers.
Table 2. Cost and time analysis
TIME COST
SP* EP*
Single assay SP* EP* Single assayRange Mean Range Mean
Classical karyotype 10–20 days 17 days – – 17 days 1 – 1
Rapid FISH 40–48 h 43 h + 24 h 67 h – 44 h 0.78 1.2 0.8
Microfluidics-FISH 8–24 h 20 h +24 h 34 h – 21.5 h 0.35 0.55 0.37
*SP — standard protocol; EP — extended protocol
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 The role of FISH based method as the only applied test 
in prenatal diagnosis has not been clearly defined and va-
rying strategies maybe be adopted in different facilities. Yet 
affordable price and accelerated turnaround time of Micro-
fluidics-FISH make it a valuable additional or exclusive test 
that allows to alleviate parental anxiety and advance further 
care and pregnancy management.
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